OC
VIRX

Oarsman Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Oarsman Capital’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$161 – 903
2024
Q4 		$161 Hold
1,000
– – ﹤0.01% 893
2024
Q3 		$231 Buy
+1,000
New +$367 ﹤0.01% 896

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Oarsman Capital's VIRX Position: Q1 2025 in Review

Oarsman Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 1,000 shares — an estimated $161 sold.

Oarsman Capital first reported a position in VIRX in Q3 2024 and held it in 2 quarters. The position peaked at $231 in Q3 2024. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Oarsman Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Oarsman Capital sold 1,000 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $161.
  • Oarsman Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2024 and held it in 2 quarters.
  • Oarsman Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $231 in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.